-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Belgian pharmaceutical giant UCB recently announced that it has obtained an imported drug license (IDL) from China's State Drug Administration (NMPA) for the anti-epileptic drug Vimpat (lacosamide), which will enable Vimpat to be launched in China for the treatment of people with epilepsy. Specifically, Vimpat's adaptation in China is: as an auxiliary treatment drug for the treatment of partial seizures (accompanied or not accompanied by secondary systemic seizures) in adolescents and adults 16 years of age and older.
, there are nearly 10 million people with epilepsy in China, and about 400,000 new diagnoses are made each year. Vimpat's approval is an important milestone for the vast number of people with epilepsy in China and will provide an exciting new treatment option for the epilepsy community. Poorly controlled seizures have led to an unemployment rate of nearly 70 percent for people with epilepsy in China, according to a national survey. This suggests that there is a clear need for drugs in patients with epilepsy to better control and manage the condition.
Vimpat is a new type of NMDA subject glycine point combined with antagonists, belongs to a new class of functional amino acids, is a new dual-acting mechanism of anticonvulsant drugs. Compared with other anti-epileptic drugs, Vimpat has the activity of regulating sodium ion channels, which have very important functions in regulating nervous system activity and promoting conduction between nerve cells, and can control the activity of nerve cells by reducing the overactive sodium ion channel.
In the European Union, Vimpat was first approved in September 2008 as an ancillary drug for the treatment of partial seizure epilepsy (accompanied or not accompanied by secondary comprehensive seizure epilepsy) in children, adolescents and adults aged 4 years and older. In EU countries, Vimpat's dosage forms are thin-film coats, syrups, and injections. Vimpat injections are an alternative dosage form in patients who are temporarily unable to be given oral medication.
, Vimpat tablets, oral solutions and intravenous fluids are listed in Korea, Hong Kong, Malaysia, the Philippines, Thailand and Japan. (Bio Valley)
